These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28714403)

  • 1. GSK3 Inhibitors in the Therapeutic Development of Diabetes, Cancer and Neurodegeneration: Past, Present and Future.
    Maqbool M; Hoda N
    Curr Pharm Des; 2017 Nov; 23(29):4332-4350. PubMed ID: 28714403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease.
    Maqbool M; Mobashir M; Hoda N
    Eur J Med Chem; 2016 Jan; 107():63-81. PubMed ID: 26562543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease.
    Gao C; Hölscher C; Liu Y; Li L
    Rev Neurosci; 2011 Dec; 23(1):1-11. PubMed ID: 22718609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes.
    Wagman AS; Johnson KW; Bussiere DE
    Curr Pharm Des; 2004; 10(10):1105-37. PubMed ID: 15078145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycogen synthase kinase 3: a drug target for CNS therapies.
    Bhat RV; Budd Haeberlein SL; Avila J
    J Neurochem; 2004 Jun; 89(6):1313-7. PubMed ID: 15189333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute selective glycogen synthase kinase-3 inhibition enhances insulin signaling in prediabetic insulin-resistant rat skeletal muscle.
    Dokken BB; Sloniger JA; Henriksen EJ
    Am J Physiol Endocrinol Metab; 2005 Jun; 288(6):E1188-94. PubMed ID: 15671078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycogen synthase kinase 3: more than a namesake.
    Rayasam GV; Tulasi VK; Sodhi R; Davis JA; Ray A
    Br J Pharmacol; 2009 Mar; 156(6):885-98. PubMed ID: 19366350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GSK3 inhibitors and disease.
    Hernández F; Nido JD; Avila J; Villanueva N
    Mini Rev Med Chem; 2009 Aug; 9(9):1024-9. PubMed ID: 19689399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycogen Synthase Kinase 3 (GSK3): Its Role and Inhibitors.
    Wadhwa P; Jain P; Jadhav HR
    Curr Top Med Chem; 2020; 20(17):1522-1534. PubMed ID: 32416693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence that the dephosphorylation of Ser(535) in the epsilon-subunit of eukaryotic initiation factor (eIF) 2B is insufficient for the activation of eIF2B by insulin.
    Wang X; Janmaat M; Beugnet A; Paulin FE; Proud CG
    Biochem J; 2002 Oct; 367(Pt 2):475-81. PubMed ID: 12133000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance.
    Højlund K
    Dan Med J; 2014 Jul; 61(7):B4890. PubMed ID: 25123125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.
    Avila J; Wandosell F; Hernández F
    Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
    Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
    J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A new target for diabetes therapy: advances in the research of glycogen synthase kinase-3 inhibitors].
    Liu SN; Shen ZF
    Yao Xue Xue Bao; 2007 Dec; 42(12):1227-31. PubMed ID: 18338632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges and opportunities with glycogen synthase kinase-3 inhibitors for insulin resistance and Type 2 diabetes treatment.
    Eldar-Finkelman H; Ilouz R
    Expert Opin Investig Drugs; 2003 Sep; 12(9):1511-9. PubMed ID: 12943495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycogen synthase kinase 3 alteration in Alzheimer disease is related to neurofibrillary tangle formation.
    Baum L; Hansen L; Masliah E; Saitoh T
    Mol Chem Neuropathol; 1996; 29(2-3):253-61. PubMed ID: 8971700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycogen synthase kinase-3 inhibitors suppress the AR-V7-mediated transcription and selectively inhibit cell growth in AR-V7-positive prostate cancer cells.
    Nakata D; Koyama R; Nakayama K; Kitazawa S; Watanabe T; Hara T
    Prostate; 2017 Jun; 77(9):955-961. PubMed ID: 28397338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Conundrum of GSK3 Inhibitors: Is it the Dawn of a New Beginning?
    Bhat RV; Andersson U; Andersson S; Knerr L; Bauer U; Sundgren-Andersson AK
    J Alzheimers Dis; 2018; 64(s1):S547-S554. PubMed ID: 29758944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estradiol inhibits GSK3 and regulates interaction of estrogen receptors, GSK3, and beta-catenin in the hippocampus.
    Cardona-Gomez P; Perez M; Avila J; Garcia-Segura LM; Wandosell F
    Mol Cell Neurosci; 2004 Mar; 25(3):363-73. PubMed ID: 15033165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.